Literature DB >> 25671827

Anti-hepatitis C virus seropositivity is not associated with metabolic syndrome irrespective of age, gender and fibrosis.

Yuan-Lung Cheng1, Yuan-Chen Wang2, Keng-Hsin Lan3, Teh-Ia Huo3, Yi-Hsiang Huang3, Chien-Wei Su3, Han-Chieh Lin3, Fa-Yauh Lee3, Jaw-Ching Wu4, Shou-Dong Lee2.   

Abstract

Although many studies have tried to clarify the association between hepatitis C virus (HCV) infection and metabolic syndrome, few studies have comprehensively assessed their relationship stratified by different demographic characteristics. We aimed to investigate the correlation between metabolic syndrome and anti-HCV seropositivity in Taiwan. This study enrolled consecutive subjects who had received health check-up services at Taipei Veterans General Hospital from 2002 to 2009. Metabolic syndrome was diagnosed according to the criteria defined by the International Diabetes Federation Task Force on Epidemiology and Prevention. Among the 30616 subjects enrolled in this study, the prevalence of positive anti-HCV serology was 2.7%, and 28.8% were diagnosed with metabolic syndrome. By multivariate analysis, metabolic syndrome was associated with higher body mass index, older age, male sex, a higher level of alanine aminotransferase, gamma-glutamyltransferase, platelet count and the presence of fatty liver whereas anti-HCV seropositivity was not an independent variable for metabolic syndrome. Further stratifying the subjects by age and sex, and there was still no significant difference in HCV status between those with and without metabolic syndrome. Moreover, the stage of liver fibrosis represented by aspartate aminotransferase to platelet ratio index was also not correlated with metabolic syndrome in the subjects with anti-HCV seropositivity. In conclusion, although subjects with anti-HCV seropositivity had higher fasting glucose levels and lower cholesterol and triglyceride levels compared to those with negative anti-HCV test, anti-HCV seropositivity was not associated with metabolic syndrome based on the current diagnostic criteria irrespective of age, gender and the stage of hepatic fibrosis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25671827

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  10 in total

1.  Retrospective study of the associations between hepatitis C virus infection and metabolic factors.

Authors:  Shira Yair-Sabag; Elchanan Nussinson; Ofir Ben-Assuli; Fahmi Shibli; Azmi Shahbari; Shira Zelber-Sagi
Journal:  World J Hepatol       Date:  2016-10-28

2.  Fatty Liver Index and Lipid Accumulation Product Can Predict Metabolic Syndrome in Subjects without Fatty Liver Disease.

Authors:  Yuan-Lung Cheng; Yuan-Jen Wang; Keng-Hsin Lan; Teh-Ia Huo; Yi-Hsiang Huang; Chien-Wei Su; Wei-Yao Hsieh; Ming-Chih Hou; Han-Chieh Lin; Fa-Yauh Lee; Jaw-Ching Wu; Shou-Dong Lee
Journal:  Gastroenterol Res Pract       Date:  2017-01-17       Impact factor: 2.260

3.  High health literacy is associated with less obesity and lower Framingham risk score: Sub-study of the VGH-HEALTHCARE trial.

Authors:  Yuan-Lung Cheng; Jiah-Hwang Shu; Hsiu-Chuan Hsu; Ying Liang; Ruey-Hsing Chou; Pai-Feng Hsu; Yuan-Jen Wang; Yaw-Zon Ding; Teh-Ling Liou; Ying-Wen Wang; Shao-Sung Huang; Chung-Chi Lin; Tse-Min Lu; Hsin-Bang Leu; Shing-Jong Lin; Wan-Leong Chan
Journal:  PLoS One       Date:  2018-03-28       Impact factor: 3.240

4.  Chronic Viral Hepatitis and Metabolic Syndrome/Cardiovascular Risk.

Authors:  Peter Jarcuska; Ahmed Abdel-Razik; Robert Flisiak; Ram B Singh
Journal:  Can J Gastroenterol Hepatol       Date:  2018-11-04

5.  The association of hepatitis c virus infection status with serum glucose levels.

Authors:  Yinping Li; Xiaomei Wang; Ge Yu; Haibo Sun; Juan Lv; Xiumei Chi; Ruihong Wu; Xiuzhu Gao; Junqi Niu
Journal:  BMC Gastroenterol       Date:  2019-06-13       Impact factor: 3.067

6.  The irreversible HCV-associated risk of gastric cancer following interferon-based therapy: a joint study of hospital-based cases and nationwide population-based cohorts.

Authors:  Chun-Wei Chen; Jur-Shan Cheng; Tai-Di Chen; Puo-Hsien Le; Hsin-Ping Ku; Ming-Ling Chang
Journal:  Therap Adv Gastroenterol       Date:  2019-06-17       Impact factor: 4.409

7.  Association between Hepatitis C Virus Infection and Esophageal Cancer: An Asian Nationwide Population-Based Cohort Study.

Authors:  Yin-Yi Chu; Jur-Shan Cheng; Ting-Shu Wu; Chun-Wei Chen; Ming-Yu Chang; Hsin-Ping Ku; Rong-Nan Chien; Ming-Ling Chang
Journal:  J Clin Med       Date:  2021-05-28       Impact factor: 4.241

8.  Sexual Dimorphic Metabolic Alterations in Hepatitis C Virus-infected Patients: A Community-Based Study in a Hepatitis B/Hepatitis C Virus Hyperendemic Area.

Authors:  Jing-Hong Hu; Mei-Yen Chen; Chau-Ting Yeh; Huang-Shen Lin; Ming-Shyan Lin; Tung-Jung Huang; Ming-Ling Chang
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

Review 9.  Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy.

Authors:  Sylvia Drazilova; Jakub Gazda; Martin Janicko; Peter Jarcuska
Journal:  Can J Gastroenterol Hepatol       Date:  2018-08-13

10.  Hepatitis C-associated late-onset schizophrenia: a nationwide, population-based cohort study.

Authors:  Jur-Shan Cheng; Jing-Hong Hu; Ming-Yu Chang; Ming-Shyan Lin; Hsin-Ping Ku; Rong-Nan Chien; Ming-Ling Chang
Journal:  J Psychiatry Neurosci       Date:  2021-11-02       Impact factor: 6.186

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.